Dr Janine Stutterheim speaks to ecancer about a study she presented at the virtual ASH 2020 meeting on the clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
She initially talks about the aims and objectives of the study which was to detect MRD in paediatric ALL patients to investigate the prognosis and best treatment pathway for these patients.
She then explains the methodology used in this paper and highlighted the key results observed.
Dr Stutterheim on asking, also explained what MRD was and how it could be helpful.
She concludes by discussing how the results from this study could impact the future treatment of paediatric ALL patients.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.